Ocugen Signs License Deal for OCU400 in MENA Region
Ocugen entered a binding term sheet with Roots Pharmaceutical for the exclusive license of OCU400 in the MENA region. The agreement provides up to $255 million in sales milestones and underscores Ocugen's strategic expansion into emerging markets for gene therapies.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day